Insys Therapeutics Inc (NASDAQ:INSY) Shifting Institutional Investors Sentiment

Sentiment for Insys Therapeutics Inc (NASDAQ:INSY)

Insys Therapeutics Inc (NASDAQ:INSY) institutional sentiment increased to 1.16 in Q1 2019. Its up 0.33, from 0.83 in 2018Q4. The ratio improved, as 37 hedge funds opened new or increased stock positions, while 32 sold and reduced stakes in Insys Therapeutics Inc. The hedge funds in our partner’s database reported: 11.04 million shares, up from 9.65 million shares in 2018Q4. Also, the number of hedge funds holding Insys Therapeutics Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 20 Reduced: 12 Increased: 23 New Position: 14.

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $99.46 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.

The stock increased 13.91% or $0.16 during the last trading session, reaching $1.31. About 3.72M shares traded or 174.83% up from the average. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 83.83% since June 9, 2018 and is downtrending. It has underperformed by 88.26% the S&P500.

Raging Capital Management Llc holds 0.2% of its portfolio in INSYS Therapeutics, Inc. for 295,790 shares. Jump Trading Llc owns 42,400 shares or 0.06% of their US portfolio. Moreover, Gam Holding Ag has 0.02% invested in the company for 83,940 shares. The New York-based Millennium Management Llc has invested 0.01% in the stock. Panagora Asset Management Inc, a Massachusetts-based fund reported 438,606 shares.

INSYS Therapeutics, Inc. (NASDAQ:INSY) Ratings Coverage

Ratings analysis reveals 75% of Insys Therapeutics’s analysts are positive. Out of 4 Wall Street analysts rating Insys Therapeutics, 3 give it “Buy”, 1 “Sell” rating, while 0 recommend “Hold”. The lowest target is $4 while the high is $11. The stock’s average target of $7.75 is 491.60% above today’s ($1.31) share price. INSY was included in 8 notes of analysts from December 19, 2018. The firm earned “Buy” rating on Friday, March 8 by Janney Capital. Cantor Fitzgerald maintained INSYS Therapeutics, Inc. (NASDAQ:INSY) on Monday, February 25 with “Buy” rating. Piper Jaffray maintained the stock with “Sell” rating in Friday, March 8 report. Cantor Fitzgerald maintained INSYS Therapeutics, Inc. (NASDAQ:INSY) on Thursday, March 7 with “Buy” rating. Janney Capital reinitiated the stock with “Buy” rating in Wednesday, December 19 report. RBC Capital Markets maintained it with “Outperform” rating and $7 target in Friday, March 8 report.

More notable recent INSYS Therapeutics, Inc. (NASDAQ:INSY) news were published by: Seekingalpha.com which released: “Why Insys Therapeutics Is Unlikely To Survive – Seeking Alpha” on May 16, 2019, also Seekingalpha.com with their article: “Insys Therapeutics Is Ready To Change Lanes And Shift Gears In 2019 – Seeking Alpha” published on February 19, 2019, Nasdaq.com published: “Insys Therapeutics (INSY) Q3 Earnings Preview: What’s in the Cards? – Nasdaq” on October 29, 2018. More interesting news about INSYS Therapeutics, Inc. (NASDAQ:INSY) were released by: Globenewswire.com and their article: “INSYS Therapeutics Implements Leadership Changes Nasdaq:INSY – GlobeNewswire” published on April 15, 2019 as well as Nasdaq.com‘s news article titled: “5 Best Marijuana Stocks in February — Are They Buys Now? – Nasdaq” with publication date: March 04, 2019.